Entera Bio Ltd.(ENTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.6M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ENTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Entera Bio Ltd. (ENTX), a Healthcare sector company. ENTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Entera Bio Ltd. reports net income of $-3.5M, free cash flow of $-3.1M. Top institutional holders of ENTX by reported 13-F value include Knoll Capital Management,, RENAISSANCE TECHNOLOGIES, Parkman Healthcare Partners, based on the most recent SEC filings. ENTX trades on the Nasdaq exchange and files with the SEC under CIK 1638097. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entera Bio Ltd. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-3.5M
Free Cash Flow
Q1 2026
$-3.1M
Get alerted when ENTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Entera Bio Ltd. including:
Top Institutional Holders of ENTX
Knoll Capital Management, LLC
$6.5M5,881,879 shRENAISSANCE TECHNOLOGIES LLC
$525.5K473,442 shParkman Healthcare Partners LLC
$320.4K288,670 shCITADEL ADVISORS LLC
$272.6K245,577 shSeven Fleet Capital Management LP
$228.2K205,542 shMARSHALL WACE, LLP
$217.3K195,780 shNORTHERN TRUST CORP
$163.0K146,854 shXTX Topco Ltd
$146.1K131,622 shSchonfeld Strategic Advisors LLC
$61.3K55,223 shSIGNATURE ESTATE & INVESTMENT ADVISORS LLC
$52.5K47,328 sh
| Fund | Value | Shares |
|---|---|---|
| Knoll Capital Management, LLC | $6.5M | 5,881,879 |
| RENAISSANCE TECHNOLOGIES LLC | $525.5K | 473,442 |
| Parkman Healthcare Partners LLC | $320.4K | 288,670 |
| CITADEL ADVISORS LLC | $272.6K | 245,577 |
| Seven Fleet Capital Management LP | $228.2K | 205,542 |
| MARSHALL WACE, LLP | $217.3K | 195,780 |
| NORTHERN TRUST CORP | $163.0K | 146,854 |
| XTX Topco Ltd | $146.1K | 131,622 |
| Schonfeld Strategic Advisors LLC | $61.3K | 55,223 |
| SIGNATURE ESTATE & INVESTMENT ADVISORS LLC | $52.5K | 47,328 |
More Healthcare Companies
View all Healthcare →Put ENTX on your watchlist
Track score changes the day Entera Bio Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ENTX a good stock to buy?
13F Pro's AI-powered analysis of Entera Bio Ltd. (ENTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENTX are available on the ENTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ENTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Entera Bio Ltd.'s investment landscape.